BioNTech’s Bold Leap: From COVID-19 Success to Cutting-Edge Cancer Therapies
BioNTech is pivoting from COVID-19 vaccines to cancer therapies, leveraging mRNA technology. Despite a decline in quarterly profits, Q4 2024 earnings per share (EPS) of 1.08 euros exceeded expectations. The…